Coherus and Junshi Present Interim Results of Toripalimab in P-III JUPITER-06 Trial as 1L Treatment for Advanced Esophageal Squamous Cell Carcinoma at ESMO 2021

 Coherus and Junshi Present Interim Results of Toripalimab in P-III JUPITER-06 Trial as 1L Treatment for Advanced Esophageal Squamous Cell Carcinoma at ESMO 2021

Coherus Report Results of CHS-201 (biosimilar, ranibizumab) in COLUMBUS-AMD Clinical Trial for the Treatment of nAMD

Shots:

  • The P-III JUPITER-06 trial evaluates toripalimab + CT vs PBO + CT in a ratio (1:1) in 514 treatment-naive patients with advanced or metastatic ESCC
  • The study met its co-primary 1EPs i.e., improvements in PFS & OS compared to CT alone. At a prespecified interim analysis on Mar 22, 2021 @median follow-up of 7.4 &7.3mos.; m-OS (17.0 vs 11.0mos.); OS rates @1yrs. (66.0% vs 43.7%); grade ≥3 AEs (73.2% vs 70.0%) & fatal AEs were similar i.e., 8.2% & no new safety signals were observed
  • The companies plan to submit a BLA for toripalimab to the US FDA for the same indication in 2022. In early 2021, Coherus got in-licensed rights to develop and commercialize toripalimab in the US and Canada

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Coherus

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post